Wyeth

QPS Bolsters New Translational Medicine Group

Wednesday, August 6, 2008 07:28 AM

Newark, Del.-based QPS, a provider of research services for the pharmaceutical industry, named Dr. LingSing K. Chen to head its new Translational Medicine department.

“In its Critical Path Initiative, the FDA identified—correctly, we believe—the need for this country to make significant improvements to the process under which new drugs are developed,” said Dr. Ben Chien, QPS president and chief executive officer. “By adding a department of Translational Medicine, we hope to play an integral role in the process of moving research discoveries from the laboratory into clinical practice more rapidly.”

Translational medicine is a scientific discipline that refers to the translation of basic research into new therapies for patients.

“The remarkable growth in our biomarkers business areas led us to consider this path,” Dr. Chien said. “QPS considers the creation of a Translational Medicine department pivotal to providing new technologies to support preclinical and clinical drug development worldwide.”

Chien noted that many QPS clients have already formed Translational Medicine units to facilitate the interaction between basic research and clinical medicine, particularly in clinical trials.

Chien said QPS would combine two existing groups, Immunobiomarker and Molecular Biology, to form the new department. Dr. LingSing K. Chen, former executive director of the Molecular Biology group, will head QPS’ new Translational Medicine department.

“Dr. Chen is a founding member of our Molecular Biology group and has established very diverse capabilities within a short period of time,” Chien said. “She is a determined leader with a great deal of entrepreneurial spirit and I have every reason to believe in the success of our new venture.”

Prior to joining QPS, Chen held executive positions at Wyeth Pharmaceuticals and as a senior advisor to the Industrial Technology Research Institute (ITRI) in Taiwan.

More... »

Wyeth Overhauling Phase II Program

Tuesday, July 18, 2006 08:19 AM

Wyeth plans to make bold changes to its phase II program, cutting the number of sites participating and using more sites in China, India, Latin America and Central and Eastern Europe. Wyeth also plans to use more sites in emerging regions for its entire clinical program.

More... »

CenterWatch’s 42nd Annual DIA Round Up

Monday, June 26, 2006 10:57 AM

This year’s Drug Information Association (DIA) 42nd annual industry conference, held in Philadelphia, Penn attracted nearly 10,000 attendees from across every sector in the drug development industry. Presenting at the show were over 400 U.S. and close to 200 international companies, from both developed markets and emerging regions around the globe. Nearly 1,000 delegates from 50 countries were scheduled to attend.

More... »

We Found The Best Clinical Site Sponsor Companies

Friday, March 31, 2006 02:41 PM

Contract and budget issues for sponsor sites are most likely to bog down clinical studies, but Wyeth is one of the best in the industry at managing the process.

More... »